alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
#### The People of the State of New York, Respondent, v Tyrone Hecker, Appellant.

[962 NYS2d 619]

Judgments, Supreme Court, New York County (Ronald A. Zweibel, J.), rendered December 17, 2008, convicting defendant, upon his pleas of guilty, of robbery in the first and third degrees, and sentencing him, as a second violent felony offender and as a second felony offender, to consecutive terms of 10 years and 2 to 4 years, respectively, unanimously affirmed.

Defendant’s contention that the court erred in granting him an unduly limited suppression hearing is unpreserved, as well as being forfeited by defendant’s guilty plea. Rather than issuing an order that finally denied any part of defendant’s suppression motion, which would be a prerequisite for appellate review *(see*CPL 710.70 [2]), the court ordered a hearing. While the court’s order contained language limiting the issues that could be raised at the hearing, and the limiting language (which appears to have been inserted inadvertently) was inapplicable to the fact pattern, it was incumbent upon defendant to alert the court to the problem. Instead, defendant pleaded guilty before any hearing was held, thereby forfeiting review *(see People v Fernandez,*67 NY2d 686, 688 [1986]).

*607We perceive no basis for reducing the sentences or directing that they run concurrently.

Concur—Gonzalez, EJ., Mazzarelli, Moskowitz, Renwick and Manzanet-Daniels, JJ.
[Federal Register Volume 74, Number 100 (Wednesday, May 27, 2009)]
[Notices]
[Page 25261]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: E9-12191]



[[Page 25261]]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Center for Complementary & Alternative Medicine; Notice 
of Closed Meeting

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. App.), notice is hereby given of the following 
meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Center for Complementary and 
Alternative Medicine Special Emphasis Panel; ARRA Type 3 Basic 
Science R21 applications.
    Date: June 14-16, 2009.
    Time: 6 p.m. to 5 p.m.
    Agenda: To review and evaluate grant applications.
    Place: Residence Inn Bethesda, 7335 Wisconsin Avenue, Bethesda, 
MD 20814.
    Contact Person: Peter Kozel, PhD, Scientific Review Officer, 
NCCAM, 6707 Democracy Boulevard, Suite 401, Bethesda, MD 20892-5475, 
301-496-8004, <a href="/cdn-cgi/l/email-protection#5a3135203f362a1a373b333674343332743d352c"><span class="__cf_email__" data-cfemail="4b2024312e273b0b262a222765252223652c243d">[email protected]</span></a>.

(Catalogue of Federal Domestic Assistance Program No. 93.701, ARRA 
Related Biomedical Research and Research Support Awards, National 
Institutes of Health, HHS)

    Dated: May 15, 2009.
Jennifer Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. E9-12191 Filed 5-26-09; 8:45 am]
BILLING CODE 4140-01-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>
EXHIBIT 32.2

                            CERTIFICATION PURSUANT TO
                             18 U.S.C. SECTION 1350,
                             AS ADOPTED PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002



         In connection with the Quarterly  Report of Cistera  Networks,  Inc. on
Form 10-QSB for the period  ending June 30, 2007,  as filed with the  Securities
and Exchange  Commission  on the date hereof (the  "Report"),  I, Cynthia  Garr,
Interim C.F.O. of the Company,  certify,  pursuant to 18 U.S.C. Section 1350, as
adopted pursuant to Section 906 of the  Sarbanes-Oxley Act of 2002, that, to the
best of my knowledge and belief:

         (1) the Report fully complies with the requirements of Section 13(a) or
15(d) of the Securities Exchange Act of 1934; and

         (2) the  information  contained in the Report fairly  presents,  in all
material  respects,  the  financial  condition  and result of  operations of the
Company.


/s/    Cynthia A. Garr
-------------------------------
Cynthia A. Garr
Chief Financial Officer
(Principal Financial Officer)


August 14, 2007


A signed  original of this written  statement  required by Section 906, or other
document authenticating, acknowledging, or otherwise adopting the signature that
appears in typed form within the  electronic  version of this written  statement
has been  provided  to the  Company  and will be  retained  by the  Company  and
furnished to the Securities and Exchange Commission or its staff upon request.
```

[Federal Register Volume 74, Number 99 (Tuesday, May 26, 2009)]
[Notices]
[Pages 24853-24854]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: E9-12110]

=======================================================================
-----------------------------------------------------------------------

FEDERAL RESERVE SYSTEM

Notice of Proposals to Engage in Permissible Nonbanking 
Activities or to Acquire Companies that are Engaged in Permissible 
Nonbanking Activities

    The companies listed in this notice have given notice under section 
4 of the Bank Holding Company Act (12 U.S.C. 1843) (BHC Act) and 
Regulation Y (12 CFR Part 225) to engage de novo, or to acquire or 
control voting securities or

[[Page 24854]]

assets of a company, including the companies listed below, that engages 
either directly or through a subsidiary or other company, in a 
nonbanking activity that is listed in Sec. [thinsp]225.28 of Regulation 
Y (12 CFR 225.28) or that the Board has determined by Order to be 
closely related to banking and permissible for bank holding companies. 
Unless otherwise noted, these activities will be conducted throughout 
the United States.
    Each notice is available for inspection at the Federal Reserve Bank 
indicated. The notice also will be available for inspection at the 
offices of the Board of Governors. Interested persons may express their 
views in writing on the question whether the proposal complies with the 
standards of section 4 of the BHC Act. Additional information on all 
bank holding companies may be obtained from the National Information 
Center website at www.ffiec.gov/nic/.
    Unless otherwise noted, comments regarding the applications must be 
received at the Reserve Bank indicated or the offices of the Board of 
Governors not later than June 9, 2009.
    A. Federal Reserve Bank of Chicago (Colette A. Fried, Assistant 
Vice President) 230 South LaSalle Street, Chicago, Illinois 60690-1414:
    1. West Suburban Bancorp, Inc., Lombard, Illinois; to engage de 
novo in extending credit and servicing loans, pursuant to section 
225.28(b)(1) of Regulation Y.

    Board of Governors of the Federal Reserve System, May 20, 2009.
Robert deV. Frierson,
Deputy Secretary of the Board.
[FR Doc. E9-12110 Filed 5-22-09; 8:45 am]
BILLING CODE 6210-01-S
```
#### The People of the State of New York, Respondent, v John Santos, Appellant.

[963 NYS2d 380]

*1065Appeal by the defendant from a judgment of the Supreme Court, Queens County (Lasak, J.), rendered May 2, 2007, convicting him of burglary in the second degree, criminal possession of stolen property in the fifth degree, petit larceny, criminal mischief in the fourth degree, and possession of burglar’s tools, upon a jury verdict, and imposing sentence.

Ordered that the judgment is affirmed.

The defendant’s *Batson*challenge *(see Batson v Kentucky,*476 US 79 [1986]) was properly denied, as he failed to make the requisite prima facie showing of discrimination. The defendant relied solely on the number of Latino venirepersons that were challenged to support his request for race-neutral explanations, and offered no showing of circumstances sufficient to raise an inference of a pattern of discrimination *(see People v Brown,*97 NY2d 500, 507-508 [2002]; *People v Diaz,*59 AD3d 459 [2009]; *People v Severino,*44 AD3d 1077 [2007]; *People v Thigpen,*14 AD3d 518 [2005]).

The defendant’s contention that certain comments made by the prosecutor during summation constituted reversible error is unpreserved for appellate review, since the defendant made only general objections to several comments, did not request curative instructions when the objections were sustained, and did not timely move for a mistrial *(see*CPL 470.05 [2]; *People v White,*5 AD3d 511 [2004]). In any event, the defendant’s contention is without merit because the challenged remarks were a fair response to the defense summation *(see People v Ashwal,*39 NY2d 105 [1976]; *People v Diaz,*59 AD3d at 459; *People v Lawson,*40 AD3d 657, 658 [2007]; *People v Martinez,*17 AD3d 484, 485 [2005]; *People v Indelecio,*8 AD3d 406, 407 [2004]).

The defendant’s remaining contention is without merit.

Dillon, J.P, Balkin, Austin and Cohen, JJ., concur.
## Breadcrumb

-  Home 
-  News & Events 
-  NIDCD News 

# 2015 News Items

                - December 10 Speaker Series Talk: “How NIDCD research is preventing or reversing hearing loss”   (11/24/2015)
                - NIH researchers pinpoint additional gene tied to persistent stuttering  (11/06/2015)
                - Problems with ability to smell or taste common in middle-aged and older adults  (10/29/2015)
                - Gene therapy corrects stereocilia defects in the inner ears of mice with inherited deafness  (10/23/2015)
                - NIDCD observes International Stuttering Awareness Day  (10/22/2015)
                - Scientists develop genetic blueprint of inner ear cell development  (10/15/2015)
                - High-fidelity stereocilia (NIH Intramural Research Program)  (10/13/2015)
                - Researchers identify two forms of molecular motor protein necessary for hearing  (10/06/2015)
                - New prevalence data shows 1 in 6 adults reports trouble hearing  (09/17/2015)
                - Advanced microscopy helps NIDCD pinpoint key proteins for hearing and balance  (09/10/2015)
                - Researchers find genetic alterations in head and neck cancers associated with HPV infection, smoking  (08/18/2015)
                - Inflammation boosts drug-induced hearing loss in mice  (07/29/2015)
                - About 1 in 12 children has a disorder related to voice, speech, language, or swallowing  (06/11/2015)
                - Alrededor de uno de cada siete adultos hispanos tiene alguna pérdida de audición  (05/28/2015)
                - Nearly 1 in 7 Hispanic/Latino adults has some hearing loss  (05/28/2015)

#### Pagination

-                Current page            1 
-                Page            2 
-  Next pageNext › 
-  Last pageLast » 

## Media Inquiries

Contact the NIDCD press office at news@nidcd.nih.gov.

## News Archive

              - 2024 
              - 2023 
              - 2022 
              - 2021 
              - 2020 
              - 2019 
              - 2018 
              - 2017 
              - 2016 
              - 2015 
              - 2014 
              - 2013
EXHIBIT
        32.1
  **CERTIFICATION
        PURSUANT TO 18 U.S.C. SECTION 1350**
 **AS
        ADOPTED PURSUANT TO SECTION 906**
 **OF
        THE SARBANES-OXLEY ACT OF 2002**
 
 In
        connection with the Annual Report of OCTuS, Inc. (the "Company") on Form
        10-KSB
        for the year ended December 31, 2006 as filed with the Securities and Exchange
        Commission on the date hereof (the "Report"), I, Josie Ben Rubi, Chief Executive
        Officer, hereby certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant
        to Section 906 of the SARBANES-OXLEY Act of 2002, that to his
        knowledge:
 
 1.
        The
        Report fully complies with the requirements of Section 13(a) or 15(d) of
        the
        Securities Exchange Act of 1934; and
 
 2.
        The
        information contained in the Report fairly presents, in all material respects,
        the financial condition and results of operation of the Company.
  /s/ Josie
                Ben
                RubiJosie
                  Ben Rubi
                Chief
                  Executive Officer
                April
                  12, 2007
  EXHIBIT
        32.1
  **CERTIFICATION
        PURSUANT TO 18 U.S.C. SECTION 1350**
 **AS
        ADOPTED PURSUANT TO SECTION 906**
 **OF
        THE SARBANES-OXLEY ACT OF 2002**
 
 In
        connection with the Annual Report of OCTuS, Inc. (the "Company") on Form
        10-KSB
        for the year ended December 31, 2006 as filed with the Securities and Exchange
        Commission on the date hereof (the "Report"), I, Josie Ben Rubi, Principal
        Financial Officer, hereby certify pursuant to 18 U.S.C. Section 1350, as
        adopted
        pursuant to Section 906 of the SARBANES-OXLEY Act of 2002, that to his
        knowledge:
 
 1.
        The
        Report fully complies with the requirements of Section 13(a) or 15(d) of
        the
        Securities Exchange Act of 1934; and
 
 2.
        The
        information contained in the Report fairly presents, in all material respects,
        the financial condition and results of operation of the Company.
  /s/ Josie
                  Ben
                  RubiJosie
                    Ben Rubi
                  Principal
                      Financial Officer
                  April
                    12, 2007
UNPUBLISHED

UNITED STATES COURT OF APPEALS

FOR THE FOURTH CIRCUIT

No. 23-1020

RANDALL SOUSA,

Plaintiff - Appellant,

v.

CIRCUIT COURT OF FAIRFAX COUNTY; WILLBERG TEDDY 

CHAPILLIQUEN; THE HONORABLE DAVID BERNHARD; THE 

HONORABLE CHARLES S. SHARP,

Defendants - Appellees.

Appeal from the United States District Court for the Eastern District of Virginia, at 

Alexandria. Michael Stefan Nachmanoff, District Judge. (1:21-cv-01304-MSN-JFA)

Submitted: May 18, 2023 Decided: May 23, 2023

Before NIEMEYER, RICHARDSON, and RUSHING, Circuit Judges.

Dismissed by unpublished per curiam opinion.

Randall Sousa, Appellant Pro Se. Sheri H. Kelly, OFFICE OF THE ATTORNEY 

GENERAL OF VIRGINIA, Abingdon, Virginia, for Appellees.

Unpublished opinions are not binding precedent in this circuit.

USCA4 Appeal: 23-1020 Doc: 14 Filed: 05/23/2023 Pg: 1 of 2
2

PER CURIAM:

Randall Sousa seeks to appeal the district court’s order granting Defendants’ motion 

to dismiss Sousa’s civil claims. We dismiss the appeal for lack of jurisdiction because the

notice of appeal was not timely filed.

In civil cases, parties have 30 days after the entry of the district court’s final 

judgment or order to note an appeal, Fed. R. App. P. 4(a)(1)(A), unless the district court 

extends the appeal period under Fed. R. App. P. 4(a)(5) or reopens the appeal period under 

Fed. R. App. P. 4(a)(6). “[T]he timely filing of a notice of appeal in a civil case is a 

jurisdictional requirement.” Bowles v. Russell, 551 U.S. 205, 214 (2007).

The district court entered its order and judgment on November 17, 2022. Sousa

filed the notice of appeal on January 5, 2023. Because Sousa failed to file a timely notice 

of appeal or to obtain an extension or reopening of the appeal period, we dismiss the appeal. 

We dispense with oral argument because the facts and legal contentions are 

adequately presented in the materials before this court and argument would not aid the 

decisional process.

DISMISSED

USCA4 Appeal: 23-1020 Doc: 14 Filed: 05/23/2023 Pg: 2 of 2
##### 



Exhibit 32.3 CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the annual report of Centrue Financial Corporation (the Company) on Form
10-K for the year ending December 31, 2004 as filed with the Securities and Exchange Commission on
the date hereof (the Report), I, John A. Betts, Corporate Controller of the Company, certify,
pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that: (1) The Report fully complies with the requirements of section 13(a) or 15(d) of the
Securities Exchange Act of 1934; and (2) The information contained in the Report fairly presents, in all material respects, the
financial condition and result of operations of the Company. /s/ John A. Betts
John A. Betts
Corporate Controller
March 25, 2005
##### 



EXHIBIT 32.02


CERTIFICATION OF CHIEF FINANCIAL OFFICER
PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED
PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF
2002

The undersigned, the Chief Financial Officer of
Martek Biosciences Corporation (the Company), hereby
certifies that, to his knowledge, on the date hereof:



| |                                                                                                                                                                                                                                                                                                              
| | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
| | a) the annual report on Form 10-K of
    the Company for the period ended October 31, 2004 filed on
    the date hereof with the Securities and Exchange Commission
    (the Report) fully complies with the requirements of
    Section 13(a) or 15(d) of the Securities and Exchange Act
    of 1934; and
|
| | b) information contained in the Report
    fairly presents, in all material respects, the financial
    condition and results of operations of the Company.                                                                                                                                                  



| |    |                  
| | -- | -----------------
| | By | /s/ Peter L. Buzy

| |                        
| | -----------------------
| |                        
| | Peter L. Buzy          
| | Chief Financial Officer

Date: January 13, 2005

A signed original of this written statement
required by Section 906, or other document authenticating,
acknowledging, or otherwise adopting the signature that appears
in typed form within the electronic version of this written
statement required by Section 906, has been provided to
Martek Biosciences Corporation and will be retained by the
Company and furnished to the Securities and Exchange Commission
or its staff upon request.
<TABLE> <S> <C>

<PAGE>
<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE
CONDENSED BALANCE SHEETS AND STATMENTS OF OPERATIONS FOUND ON PAGES 3 AND 4 OF
THE COMPANY'S FORM 10-Q FOR THE QUARTER AND YEAR-TO-DATE ENDED MARCH 31, 1997,
AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH FINANCIAL STATEMENTS.
</LEGEND>
       
<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          DEC-31-1997
<PERIOD-START>                             JAN-01-1997
<PERIOD-END>                               MAR-31-1997
<CASH>                                       6,157,675
<SECURITIES>                                         0
<RECEIVABLES>                                1,467,322
<ALLOWANCES>                                         0
<INVENTORY>                                    991,039
<CURRENT-ASSETS>                             9,560,200
<PP&E>                                       1,099,238
<DEPRECIATION>                                       0
<TOTAL-ASSETS>                              10,706,458
<CURRENT-LIABILITIES>                        2,044,265
<BONDS>                                        550,452
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                       216,292
<OTHER-SE>                                   7,895,449
<TOTAL-LIABILITY-AND-EQUITY>                10,706,458
<SALES>                                      2,519,154
<TOTAL-REVENUES>                             2,951,204
<CGS>                                        1,240,938
<TOTAL-COSTS>                                3,660,938
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                   0
<INCOME-PRETAX>                              (653,511)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                          (653,511)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                 (653,511)
<EPS-PRIMARY>                                    (.03)
<EPS-DILUTED>                                        0
        

</TABLE>
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Health and Human Services

###### National Institutes of Health

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:*                         National Center on Minority Health and Health Disparities Special Emphasis Panel; Conference Grant Review.                    

*Date:*                         November 10, 2009.                    

*Time:*                         8 a.m. to 5 p.m.                    

*Agenda:*                         To review and evaluate grant applications.                    

*Place:*                         National Institutes of Health, Two Democracy Plaza, 6707 Democracy Boulevard, Bethesda, MD 20892 (Virtual Meeting).                    

*Contact Person:*                         Prabha L. Atreya, Ph.D, Chief, Office of Scientific Review, National Center on Minority Health and Health Disparities, 6707 Democracy Boulevard, Suite 800, Bethesda, MD 20892, (301) 594-8696,                         *atreyapr@mail.nih.gov*.                    

Dated: October 14, 2009.

Jennifer Spaeth,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. E9-25287 Filed 10-20-09; 8:45 am]

BILLING CODE 4140-01-P